Acarix AB: Positive, long term prognostic data from the Dan-NICAD I study published in European Heart Journal- Digital Health
Positive,
long term prognostic data from the Dan-NICAD I study published in European Heart Journal- Digital Health
Acarix AB (publ) today announced the publication of the Prognostic study, a study with long term follow up on patients from the Dan-NICAD 1 publication.
The long term Prognostic data from the Dan-NICAD 1 trial was first presented at the ESC Congress in September 2019 by Simon Winther, MD, PhD from Aarhus University Hospital, Denmark.
The Dan-NICAD 1 trial was initiated in September 2014 to assess non-invasive methods in patients referred to coronary CTA due to symptoms suggestive of obstructive CAD. Clinically relevant prognostic data were assessed with a median follow-up time of 3 years to evaluate the correlation between CAD-score and prognosis in patients treated by current standard of care.
LSI 2021 Emerging Medtech Summit to include 400+ Investors, Innovators and Strategics
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
MTV: Suvi Teräsniska uskoo uudelleensyntymään - meedio kertoi henkioppaasta
iltalehti.fi - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from iltalehti.fi Daily Mail and Mail on Sunday newspapers.
Acarix AB: A strong ending of an eventful year
A strong ending of an eventful year
The fourth quarter contributed strongly to our overall performance in 2020, with the market approval for CADScor from the US Food and Drug Administration (FDA) as the outstanding achievement.
Extract from CEO Per Persson s message to the End Year Report.
Fourth quarter 2020 compared with same period 2019
During the fourth quarter, 22 CADScorSystem (10, of which 4 to clinical trials) and 1,420 (1,500, of which 840 to clinical trials) disposable patches were sold to end-users and distributors.
Revenue amounted to SEK 966 thousand (774), with gross profit of SEK 713 thousand (607) and a gross margin of 74 percent (78).
Positive preliminary data from Acarix’s exploratory heart failure study SEISMO
Acarix AB (publ) today announced positive preliminary data from the exploratory SEISMO study, using its modified CADScor
®System on a potential heart failure application.
The SEISMO trial was initiated in June 2018 to evaluate the possibility of developing an algorithm that can differentiate patients referred with suspicion of heart failure. The study, with in total 199 patients at two sites in Denmark, included the last patient in 2020. Completing the inclusion to the exploratory heart failure study was a great milestone for all involved. The new data looks promising for early heart failure rule out and will be important for all affected patients today waiting all too long for a final diagnosis. The data could warrant a follow-up study to consolidate findings and bring more data for algorithm development,” said Professor Peter Søgaard, MD and primary investigator.